NNZ-2591 ( DrugBank: NNZ-2591 )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 201 | アンジェルマン症候群 | 1 |
201. アンジェルマン症候群
臨床試験数 : 24 / 薬物数 : 35 - (DrugBank : 9) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 20
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05011851 (ClinicalTrials.gov) | October 1, 2021 | 5/8/2021 | An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome | An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome | Angelman Syndrome | Drug: NNZ-2591 | Neuren Pharmaceuticals Limited | NULL | Not yet recruiting | 3 Years | 17 Years | All | 20 | Phase 2 | Australia |